Table 3.

Propensity-Adjusted Baseline and Posttreatment Uterine Fibroid Symptom Quality of Life and Visual Analog Scale Scores Among Minimally Invasive Procedures

UFS-QOL Score Component and VAS Scores	Hysterectomy (n=392)	Myomectomy (n=407)	Estimate (95% CI)	P
Baseline
Concern	38.2±29.1	38.5±29.7	−0.4 (−4.6 to 3.8)	.86
Activity	46.9±28.7	46.5±28.3	0.4 (−1.8 to 2.6)	.71
Energy/mood	46.6±27.2	46.1±26.5	0.5 (−2.0 to 3.0)	.67
Control	48.9±27.1	49.0±27.3	−0.1 (−2.1 to 2.0)	.96
Self-consciousness	46.1±32.0	46.5±32.3	−0.5 (−1.9 to 1.0)	.54
Sexual function	46.5±34.4	46.2±33.3	0.3 (−3.5 to 4.2)	.86
Total (sum of 6 subscale scores above)	45.3±25.6	45.4±24.8	−0.1 (−1.3 to 1.1)	.90
Symptom severity	58.8±23.2	58.0±23.6	0.8 (−1.7 to 3.3)	.54
VAS	70.3±20.0	71.3±19.7	−0.1 (−3.7 to 1.8)	.50
Posttreatment outcomes
Concern	86.0±28.9	74.1±30.8	12.0 (10.0 to 13.9)	<.01
Activity	77.5±27.9	74.7±27.9	2.8 (−0.6 to 6.2)	.11
Energy/mood	78.7±26.5	75.3±26.6	3.5 (−.1 to 4.9)	<.01
Control	83.0±25.8	78.0±26.0	5.1 (1.3 to 9.0)	.01
Self-consciousness	80.3±28.0	73.4±30.0	7.0 (5.5 to 8.4)	<.01
Sexual function	72.6±35.3	70.4±32.6	2.2 (−2.6 to 7.0)	.38
Total (sum of 6 subscale scores above)	80.0±25.2	75.0±25.1	5.0 (−.8 to 7.1)	<.01
Symptom severity	13.7±18.0	20.6±18.8	−6.9 (−9.0 to 4.8)	<.01
VAS	81.7±17.2	78.7±18.0	3.0 (0.6 to 5.4)	.01

UFS-QOL, Uterine Fibroid Symptom Quality of Life; VAS, visual analog scale.

Data are mean±SD unless otherwise specified.

Variables included in propensity model: age (continuous), race (African American, white, other), ethnicity (Hispanic, other), time since diagnosis with leiomyoma symptoms (continuous), prior procedures (yes or no), bleeding symptoms (yes or no), prior pregnancies (0, 1 or more) UFS-QOL components, EuroQoL 5-Dimension Health Questionnaire pain and discomfort component.